Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
DMD#43455
1
Title page
Changes in Expression of Drug-Metabolizing Enzymes by Single-walled Carbon nanotubes in
Human Respiratory Tract Cells
Kotaro Hitoshi, Miki Katoh, Tomoko Suzuki, Yoshinori Ando, and Masayuki Nadai
Pharmaceutics, Faculty of Pharmacy, Meijo University; 150 Yagotoyama, Tenpaku-ku, Nagoya
468–8503, Japan (K. H., M. K., M. N.)
Department of Materials Science and Engineering, Faculty of Science and Technology, Meijo
University; 1-501 Shiogamaguchi, Tenpaku-ku, Nagoya 468-8502, Japan (T. S., Y. A.)
DMD Fast Forward. Published on December 20, 2011 as doi:10.1124/dmd.111.043455
Copyright 2011 by the American Society for Pharmacology and Experimental Therapeutics.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
DMD#43455
2
Running title page
a) Running title: Down-regulation of CYP1A1 and CYP1B1 by SWCNTs
b) Correspondence author: Miki Katoh, Ph. D., Pharmaceutics, Faculty of Pharmacy, Meijo
University; 150 Yagotoyama, Tenpaku-ku, Nagoya 468–8503, Japan. E-mail: [email protected],
Tel: +81-52-832-1151, Fax: +81-52-834-8090
c)
Number of text pages: 28
Number of tables: 3
Number of figures: 9
Number of references: 40
Number of words in Abstract: 221
Number of words in Introduction: 501
Number of words in Discussion: 1434
d) Nonstandard abbreviations
SWCNT, single walled carbon nanotube; NHBE, normal human bronchial epithelial; DMSO,
dimethyl sulfoxide; TCDD, tetrachlorodibenzo-p-dioxin; ChIP, chromatin immunoprecipitation
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
DMD#43455
3
Abstract
Single-walled carbon nanotubes (SWCNTs) have attracted attention for biomedical and
biotechnological applications, such as drug delivery. However, there are concerns about the safety of
SWCNTs for use in humans. To investigate the potential use of SWCNTs for targeted drug delivery to
the lung, we examined their effect on drug-metabolizing enzymes in primary normal human bronchial
epithelial (NHBE) cells from 2 donors and the lung carcinoma A549 cell line. Exposure of NHBE and
A549 cells to SWCNTs dysregulated some of the important drug-metabolizing enzymes expressed in
the human respiratory organs. Exposure of NHBE cells to SWCNTs for 24 h had a pronounced effect
on expression of CYP1A1 and CYP1B1 mRNAs, which were reduced to less than 1% of control cells.
These effects were also observed in A549 cells. Exposure of A549, HepG2 hepatic carcinoma cells,
and MCF-7 breast carcinoma cells to tetrachlorodibenzo-p-dioxin induced the expression and
enzymatic activity of CYP1A1 and CYP1B1, which were also suppressed by SWCNTs, suggesting
that SWCNTs downregulated both basal and induced CYP1A1 and CYP1B1 activities. Chromatin
immunoprecipitation assays revealed that the downregulatory effect of SWCNTs may be due to
inhibition of activated aryl hydrocarbon receptor binding to the enhancer regions of the CYP1A1 and
CYP1B1 genes. Downregulation of CYP1A1 and CYP1B1 genes by SWCNTs may affect the defense
mechanisms by reducing procarcinogen bio-activation in the human lung.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
DMD#43455
4
Introduction
Nanometer-length materials, or nanomaterials, exhibit extraordinary physical and chemical
properties, which has motivated interest in their biomedical and biotechnological applications, such as
for drug delivery, gene delivery, and disease diagnosis (Lowe, 2000).
Carbon nanotubes, discovered by Iijima in 1991, are cylindrical molecules consisting of
hexagonally arranged carbon atoms (graphene sheet). They are hollow cylinders formed by rolling
single (for single-walled carbon nanotubes; SWCNTs) or multiple layers of graphene sheets. The
diameters of SWCNTs are between 0.4 and 2 nm and their lengths can reach several micrometers. The
distinct structural properties of SWCNTs allow molecules such as antibodies or drugs to be loaded
along the length of the nanotube sidewall (Liu et al., 2007).
Despite the potential advantages of SWCNTs as drug delivery carriers, there are many reports of
their negative side effects such as cytotoxicity towards cultured cells, inhalation toxicity in animals,
and effects on expression of genes involved in stress-responses and apoptosis (Alazzam et al., 2010;
Cui et al., 2005). These deleterious effects vary with the manufacturing method and the degree of
purification to remove residual catalytic metals, which may also be toxicants. We have previously
investigated the cytotoxic effect of the SWCNTs used in the present study on pulmonary carcinoma
cell lines. The results of that study showed that SWCNT exposure did not induce apoptosis or
oxidative stress at 1.0 mg/ml, the maximum concentration dispersible in cell culture medium (Hitoshi
et al., 2011).
In assessing the capacity of SWCNTs to serve as drug delivery carriers, we focused on
drug-metabolizing enzymes expressed in the human respiratory organs. Drug-metabolizing enzymes
play a central role in the metabolism, detoxification, and elimination of xenobiotics, including drugs
(Xu et al., 2005). The bronchi and lungs contains phase I enzymes such as cytochrome P450 (P450),
cyclooxygenases, and flavin-dependent monooxygenases, as well as phase II conjugating enzymes
such as glutathione S-transferases (GSTs) and UDP-glucuronyltransferases. Phase I enzymes in the
respiratory organs are mainly involved in activation of carcinogens, while phase II enzymes are
involved in their detoxification; thus, all of these enzymes play a role in early defense against
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
DMD#43455
5
pulmonary toxicity (Hukkanen et al., 2002). Targeted delivery of drugs for the treatment of lung
metastases and non-small cell lung cancer has been described (Liu et al., 2011). In addition, there is
an interesting report that intravenously injected non-functionalized SWCNTs lodged in lung tissue as
large aggregates, although polyethylene-functionalized SWCNTs did not accumulate in the lung
(Bhirde et al., 2010). Although functionalized CNTs are the mainly used for application as drug
delivery to improve dispersion and solubilization (Klumpp et al., 2006), the present study was
conducted with non-functionalized SWCNTs to clarify direct effect of SWCNTs.
The purpose of the present study was to clarify the effect of SWCNTs on drug-metabolizing
enzymes in primary normal human bronchial epithelial (NHBE) cells and A549 cells derived from
lung carcinoma. We found that CYP1A1 and CYP1B1 were the genes most affected by SWCNT
exposure, and we further examined the mechanism underlying their downregulation in basal and
induced status of these genes.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
DMD#43455
6
Materials and methods
Nanomaterials
The SWCNTs used in the present study were provided by Meijo Nano Carbon Co. Ltd (Nagoya,
Japan). SWCNTs were synthesized by the arc electrical discharge method, using nickel and yttrium as
catalysts (Ando et al., 2000). The physicochemical properties of SWCNTs are given in Table 1. The
diameters were measured by Raman spectrometry (HoloSpec, Kaiser Optical Systems, Ann Arbor,
MI), and the lengths were determined using a transmission electron microscope (TEM) (H-7000,
Hitachi, Tokyo, Japan). SWCNT purity was determined by thermogravimetric-differential thermal
analysis (DTG-60, Shimadzu, Kyoto, Japan). The residual metal catalyst content was determined with
a scanning electron microscope (ABT-150F, Topcon, Tokyo, Japan) equipped with an energy
dispersive X-ray analysis system (EMAX-5770W, HORIBA, Kyoto, Japan). SWCNTs were dispersed
in cell culture medium, supplemented with 10% Fetal bovine serum (FBS), at a concentration of 0.1
mg/ml using an ultrasonic homogenizer (VC-505, Sonics & Materials, Newtown, CT). A probe tip
with a diameter of 13 mm was placed into 100 ml of the SWCNT dispersion, which was then
sonicated at 40% amplitude (200 W) for 10 min.
Chemicals
FBS and Minimum Essential Medium were purchased from Invitrogen (Carlsbad, CA). Dulbecco’s
modified Eagle medium was purchased from Nissui Pharmaceutical (Tokyo, Japan). The RNeasy Plus
Mini Kit, RT2 First Strand Kit, and RT2 Profiler PCR array (Human Drug Metabolism) were obtained
from Qiagen (Hilden, Germany). The FastPure RNA Kit and SYBR Premix Ex Taq II were obtained
from Takara Bio (Shiga, Japan), and the ReverTra Ace qPCR RT Kit was from Toyobo (Osaka, Japan).
Tetrachlorodibenzo-p-dioxin (TCDD) was obtained from AccuStandard (New Haven, CT). Anti-aryl
hydrocarbon receptor (AhR) antibodies were obtained from Santa Cruz Biotechnologies (Santa Cruz,
CA).
Cell culture
Normal human bronchial epithelial (NHBE) cells were purchased from Lonza (Basel, Switzerland).
The cells were isolated from 2 healthy male donors, both 43 years of age (referred to as donors 1 and
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
DMD#43455
7
2), and were cultured in bronchial epithelial growth medium (Lonza), as recommended by the supplier.
Human lung carcinoma A549 cells (DS Pharma Biomedical, Osaka, Japan) were cultured in
Dulbecco’s modified Eagle medium supplemented with 10% FBS. The human hepatic carcinoma cell
line HepG2 and the human breast carcinoma cell line MCF-7 (American Type Culture Collection,
Rockville, MD), were cultured in Minimum Essential Medium supplemented with 10% FBS. All cells
were cultured at 37°C in a humidified 5% CO2 atmosphere.
SWCNT internalization into NHBE cells
Where present, the SWCNT concentration for all the experiments in the present study was 0.1
mg/ml, which we previously determined to have no effect on cell viability. NHBE cells (donor 2)
were harvested to 12-well culture plate. After 24-hr exposure to 0.1 mg/ml SWCNT, the cells were
pre-fixed with 2% glutaraldehyde in 30 mM 4-(2-hydroxyethyl)-1-piperazineethane sulfonic acid
buffer, post-fixed using 2% osmium tetroxide, dehydrated in a graded ethanol series, and embedded in
epoxy resin. Ultrathin (60−80 nm) sections were cut with a LEICA-UCT ultramicrotome, post-stained
with 2% uranyl acetate and lead citrate, and viewed using a JOEL JEM-2000 EX electron microscope.
NHBE cell viability after exposure to SWCNTs
The viability of NHBE cells (donor 2) was measured after 24 h exposure to SWCNTs by evaluating
their metabolic capacity using the CellTiter-Blue viability assay (Promega, Madison, WI), as
described previously (Hitoshi et al., 2011).
NHBE RNA extraction
NHBE cells were exposed to SWCNTs at 0.1 mg/ml for 24 h. Cell culture medium without
SWCNT was used as the untreated control. Three independent experiments were performed for each
concentration. Total RNA was extracted from the cells by using the RNeasy Plus Mini Kit
immediately after the 24-h exposure. Cells from 3 wells were pooled before RNA extraction.
PCR array analysis for NHBE cells
One microgram of total RNA isolated from NHBE cells (donor 1) was used for synthesis of cDNA
using the RT2 First Strand Kit. Gene analysis was carried out using The Human Drug Metabolism
RT2 Profiler PCR array with an ABI 7500 instrument (Applied Biosystems, Foster City, CA),
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
DMD#43455
8
according to the manufacturer’s instructions. Eighty-four genes involved in drug metabolism were
analyzed. The fold change in expression of a target gene between the untreated control group and the
SWCNT-exposed group, normalized to the level of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), was determined by the comparative Ct method using the following equation: Fold change
= 2-∆(∆Ct), where ∆Ct = Ct (target gene) – Ct (GAPDH), and ∆(∆Ct) = ∆Ct (SWCNT exposed) – ∆Ct
(untreated control).
Real-time PCR analysis for NHBE and A549 cells
One microgram of total RNA was used for the reverse transcription reactions with the ReverTra
Ace qPCR RT Kit. Eleven genes of interest identified in the PCR array were selected for analysis by
real-time PCR, which was carried out with the Thermal Cycler Dice (Takara Bio) using SYBR Premix
Ex Taq II. Specific primers used in the present study are described in table 2. PCR amplification
conditions were an initial 30-s denaturation step at 95°C followed by 40 cycles of denaturation at
95°C for 5 s, and annealing and extension steps as described in Table 2. The relative expression level
of each gene was calculated using the standard curve method. All data were derived from 3
independent measurements and were normalized to the expression level of GAPDH.
Dose-responsive effect of SWCNTs on CYP1A1 and CYP1B1 mRNA expression in NHBE and
A549 cells
Total RNAs were extracted from cells incubated for 24 h with medium alone or 0.00001, 0.0001,
0.001, 0.01, and 0.1 mg/ml SWCNTs for NHBE cells (donor 2), and 0.001, 0.005, 0.01, 0.05, and 0.1
mg/ml SWCNTs for A549 cells. The reverse transcription and real-time PCR was performed
according to the methods described above. IC50 value was calculated using KaleidaGraph (HULINKS,
Tokyo, Japan)
Effect of SWCNTs on basal CYP1A1, CYP1B1, and AhR mRNAs in A549, HepG2, and MCF-7
cell lines
Total RNAs were extracted from cells incubated for 24 h with medium alone or with SWCNTs. The
reverse transcription and real-time PCR was performed according to the methods described above.
Since Beedanagari et al. (2009) has reported that CYP1B1 expression was undetectable in HepG2
cells, in the present study only CYP1A1 mRNA was investigated in HepG2 cells.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
DMD#43455
9
Effect of SWCNTs on TCDD-induced CYP1A1 and CYP1B1 in A549, HepG2, and MCF-7 cell
lines
RNA was extracted from cells after incubation for 24 h with 0.1% dimethyl sulfoxide (DMSO;
TCDD vehicle), 10 nM TCDD, or SWCNT + 10 nM TCDD. The reverse transcription and real-time
PCR was performed according to the methods described above.
Enzymatic activity
For analysis of P450 enzymatic activity, HepG2 and MCF-7 cells were allowed to attach to culture
wells for 24 h, and were then exposed to 0.1% DMSO (control), 10 nM TCDD, or 10 nM TCDD +
SWCNT for a further 24 h. After 24-h exposure, CYP1A1 and CYP1B1 activity was measured
according to the protocol of the P450-Glo CYP1A1 Assay (Promega). The substrate provided in this
assay is metabolized by both CYP1A1 and CYP1B1 to generate luciferin, and the assay therefore
reflects the combined activities of the 2 isoforms.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assays were performed to assess specific binding of AhR to
the CYP1A1 and CYP1B1 enhancers in HepG2 and MCF-7 cells. Assays were performed according
to the protocol of ChIP-IT Express (Active Motif, Carlsbad, CA). MCF-7 and HepG2 cells were
treated with 0.1% DMSO (control), 10 nM TCDD, or 10 nM TCDD + SWCNT for 24 h.
Immunoprecipitations were performed with anti-AhR antibodies overnight at 4˚C. The PCR primers
for the CYP1A1 and CYP1B1 enhancers were described previously (Matthews et al., 2005; Okino et
al., 2006).
MicroRNA analysis
MicroRNA (miRNA) was extracted with a Nucleospin miRNA isolation kit (Takara Bio) from
MCF-7 cells after treatment with 0.1% DMSO (control), 10 nM TCDD, or 10 nM TCDD + SWCNT
for 24 h. The expression of RNU38B and hsa-miR-27b was quantified using ABI 7700 (Applied
Biosystems) according to the TaqMan MicroRNA Assay protocol. All data were determined in 3
independent measurements and were normalized to the expression of RNU38B.
Statistical analysis
Statistical analyses were performed by either Student’s unpaired t-test or Bonferroni correction
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
DMD#43455
10
following ANOVA (dose-response study) using StatView software (HULINKS).
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
DMD#43455
11
Results
Characterization of SWCNTs
The diameter and the length of SWCNTs were 1.36−1.42 nm and 1−5 µm, respectively, provided as
a referential value from the manufacturer. Purity of the SWCNT was over 90% with metal catalyst
residue of nickel (0.56 atom %) and yttrium (0.16 atom %) (Table 1). Rest of the component is
amorphous carbon that does not form tubular structure. The dispersion status of 1.0 mg/ml SWCNT
has been characterized by TEM and light microscope in our previous report (Hitoshi et al., 2011).
SWCNTs could be dispersed in culture medium, supplemented with 10 % FBS, since protein
improves its dispersibility and stability.
SWCNT internalization into NHBE cells
Electron microscopy revealed dense black aggregated material in NHBE cells (donor 2) that had
been exposed to SWCNTs, but not in untreated cells (Fig. 1). The aggregate seemed to be localized in
pinocytotic vesicles (representative section indicated by the circle). We presume this material is
bundled SWCNTs. In addition, no black aggregates were detected in the nucleus of the cell and the
cell morphology was unaffected by exposure to SWCNTs. Exposure to 0.1 mg/ml SWCNTs for 24 h
had no effect on NHBE cell viability.
Changes in expression of drug metabolizing genes in NHBE and A549 cells after SWCNT
exposure
PCR array analysis was performed to assess the expression of drug-metabolizing enzymes in
NHBE cells (donor 1) after a 24-h exposure to SWCNTs. The results are shown in Fig. 2. Exposure to
SWCNTs upregulated 4 genes by greater than 2-fold and 15 were downregulated to less than 50% of
the levels in untreated control cells (Table 3). The effects of SWCNTs on the remaining genes are
shown in supplemental Table 1. Among the 84 genes, 13 genes were below the limit of detection.
Eight genes were selected from the PCR array results for further validation using real-time PCR.
Three of the selected genes were upregulated by SWCNT exposure: aldehyde dehydrogenase 1 family,
member A1 (ALDH1A1) (NM_000689), GSTA4 (NM_001512), and hydroxysteroid (17-beta)
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
DMD#43455
12
dehydrogenase 3 (HSD17B3) (NM_000197), and 5 genes were downregulated: CYP1A1
(NM_000499), CYP19A1 (NM_000103), carboxylesterase 2 (CES2) (NM_198061), glutathione
reductase (GSR) ( NM_000637), and GSTM3 (NM_000849). The results of the real-time PCR
analysis in NHBE cells (donor 1) were in good agreement with the results of the PCR array, with the
exception that GSTM3 was slightly upregulated in the real-time PCR analysis but was downregulated
in the PCR array (Table 3 and Fig. 3). In addition to these 8 genes, the expression levels of CYP1B1
(NM_000104), CYP2S1 (NM_030622), and AhR (NM_001621) were analyzed by real-time PCR.
CYP1B1 and CYP2S1 were significantly downregulated after exposure of NHBE cells to SWCNTs
and AhR was slightly upregulated. Real-time PCR analysis of these 11 genes was also performed with
NHBE (donor 2) and A549 cells. For both cell types, most of the selected genes were downregulated
after SWCNT exposure and none were significantly upregulated. SWCNT-induced downregulation of
CYP1A1, CYP1B1, CYP2S1, and CYP19A1 expression was consistent in all 3 cell types. Moreover,
the degree of CYP1A1 and CYP1B1 downregulation (to less than 1% of control cells) was consistent
in both NHBEs (donor 1 and donor 2). The degree of CYP1A1 and CYP1B1 downregulation in A549
cells was moderate compared with NHBE cells, but these isoforms were still the most affected by
SWCNTs among the selected genes.
Dose-responsive effect of SWCNTs on CYP1A1 and CYP1B1 mRNA expression in NHBE and
A549 cells
Significant dose-responsive effect of SWCNTs on CYP1A1 and CYP1B1 mRNA expression was
observed in NHBE and A549 cells at concentrations lower than 0.1 mg/ml (Fig. 4). IC50 value of
SWCNTs on expression level of CYP1A1 was 0.0024 and 0.033 mg/ml for NHBE and A549 cells,
respectively and that on CYP1B1 was 0.0025 and 0.16 mg/ml, respectively. No-observed-adverse-
effect-level on CYP1A1 and CYP1B1 mRNA expression was 0.00001 mg/ml (10 ng/ml) for NHBE
cells, based on ANOVA and Bonferroni’s test.
Effect of SWCNTs on basal and TCDD-induced CYP1A1 and CYP1B1 in A549, HepG2, and
MCF-7 cells
SWCNT exposure reduced basal CYP1A1 mRNA levels in A549, HepG2, and MCF-7 cells to 23%,
19%, and 6% of the levels in untreated control cells, respectively. In A549 and MCF-7 cells, basal
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
DMD#43455
13
CYP1B1 mRNA levels were reduced to 30% and 35%, respectively. In contrast, SWCNTs had little
effect on AhR expression in the 3 cell lines (Fig. 5).
Expression of CYP1A1 and CYP1B1 mRNA was quantified in TCDD-treated A549, HepG2, and
MCF-7 cells (Fig. 6). Addition of SWCNTs reduced the CYP1A1 mRNA levels to 3%, 8%, and 1%
of the TCDD-induced levels in A549, HepG2, and MCF-7 cells, respectively. TCDD-induced
CYP1B1 mRNA levels were also reduced by the addition of SWCNTs to 24% and 5% in A549 and
MCF-7 cells, respectively. Overall, the suppressive effect of SWCNTs on the TCDD-induced
expression of CYP1A1 and CYP1B1 was greater than on basal expression.
Enzymatic activity
The effects of SWCNTs and TCDD on the combined enzymatic activity of CYP1A1 and CYP1B1
were determined in living cells using P450-Glo analysis (Fig. 7). TCDD treatment induced the
combined enzymatic activity in HepG2 and MCF-7 cells and this was reduced to 24% and 1% of
induced levels, respectively, by the addition of SWCNTs. The enzyme activity in A549 cells was
below the limit of quantification, even after induction with TCDD.
Chromatin immunoprecipitation assay
The ChIP assay was used to examine the effects of SWCNTs and TCDD on recruitment of AhR to
the enhancer region of CYP1A1 in HepG2 cells, or to those of CYP1A1 and CYP1B1 in MCF-7 cells
(Fig. 8). Recruitment of AhR to the enhancer region of CYP1A1 was reduced to 37% by exposure of
SWCNTs. Likewise, the TCDD-induced recruitment of AhR to the enhancer regions of CYP1A1 and
CYP1B1 in MCF-7 cells were reduced to 30% and 15%, respectively. However, recruitment of AhR
to the enhancer region of CYP1A1 and CYP1B1 could not be detected in A549 cells, even after
treatment with TCDD.
MicroRNA analysis
SWCNT exposure had no significant effect on hsa-miR-27b expression in MCF-7 treated with
TCDD (Fig. 9).
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
DMD#43455
14
Discussion
The concentration of SWCNTs used in the present study was based on our previous report in which
0.1 mg/ml SWCNT had no significant effect on A549 cell viability, as assessed by metabolic capacity
and intracellular ATP content (Hitoshi et al., 2011). Here, we confirmed that SWCNT exposure also
had no effect on the viability of NHBE cells. Lower concentrations of SWCNTs have been reported to
stimulate a stress response in various cell types. For example, Sarkar et al. (2007) reported increased
expression of stress-responsive genes measured by PCR array after exposure of BJ foreskin cells to
0.06 mg/ml SWCNT for 24 h. Alazzam et al. (2010) investigated the effect on NHBE cells of a 48-h
incubation with 0.1 mg/ml SWCNT, which are the same concentration and cell type as used in the
present study. Using DNA microarray analysis, they observed dysregulation of genes involved in the
cell cycle, apoptosis, cell survival, and cell adhesion. However, NHBE cell morphology and viability
were not significantly affected by SWCNTs in the present study. In TEM analysis, visible larger
bundles of SWCNT dispersion was located only in the pinocytotic vesicles of the cells, suggesting
that these are likely to be engulfed into the cell, not penetrated the cell membrane. There are also
reports that SWCNT did not reach inside the cell (Davoren et al., 2007). However, since Porter et al.
(2007) have reported that different non-functionalized SWCNTs could be observed in lysosomes,
cytoplasm, and nucleus, using TEM and confocal microscopy. The localization of SWCNT in cells
still remains controversial and further study is needed for clarification.
Concerning P450s that are reported to be expressed in human bronchial tissue (Leclerc et al., 2010),
mRNA expression of 4 P450 isoforms, CYP1A1, CYP1B1, CYP2S1, and CYP19A1 were
significantly downregulated by SWCNTs in A549 cells, and in NHBE cells from both donors.
CYP1A1 is by far the most actively studied human pulmonary P450s due to its importance in the
metabolism of polycyclic aromatic hydrocarbons (PAH), and CYP1B1 also plays a role in activation
of PAHs (Shimada et al., 1996). In human lung tissue, expression of CYP1A1 mRNA and protein was
shown to correlate positively with the aromatic/hydrophobic DNA adduct levels (Cheng et al., 2000).
Therefore, the SWCNT-induced decreases in CYP1A1 and CYP1B1 mRNA expression observed here
may affect detoxification of xenobiotics such as PAH. CYP2S1 is also expressed in epithelial tissues
frequently exposed to xenobiotics, such as the respiratory and gastrointestinal tracts, and its
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
DMD#43455
15
expression pattern resembles that reported for CYP1B1. CYP2S1 exhibits features typical of the
CYP1 family, such as TCDD inducibility. Although the biological function of CYP2S1 is not yet fully
understood, it has been suggested to play a role in the metabolism of carcinogens (Saarikoski et al.,
2005). Therefore, we surmise that the SWCNT-induced downregulation of CYP2S1 expression
observed here may have similar significance to CYP1A1 and CYP1B1 downregulation. CYP19A1
expression was also downregulated by SWCNTs in the cell lines studied here. CYP19A1 is an
aromatase responsible for the final step in the biosynthesis of the estrogens, estradiol and estrone
(Chen et al., 2009). Dysregulation of CYP19A1 gene expression not only disrupts the balance
between estrogens and androgens, but also alters many other biochemical processes in both males and
females (Li, 2007). The observed downregulation of CYP19A1 by SWCNTs might therefore have
implications for these pathways, although further study is necessary. In contrast to CYP1A1, CYP1B1,
CYP2S1, and CYP19A1, there was no effect of SWCNTs on the expression of CYP2E1, CYP2J2, and
CYP3A5 mRNA in NHBE cells (donor 1) (supplemental Table 1), and CYP2B6 and CYP2F1 mRNA
were not detected in the PCR array analysis.
Effect of SWCNT on drug-metabolizing enzymes in NHBE cells was greater than in A549 cells,
indicating that normal cells may be more susceptible to SWCNT exposure. IC50 value of SWCNTs on
expression level of CYP1A1 was 13 times lower in NHBE cells (0.0024 and 0.033 mg/ml) that on
CYP1B1 was 64 times lower in NHBE cells (0.0025 and 0.16 mg/ml), respectively. In addition,
no-observed-adverse-effect-level on CYP1A1 and CYP1B1 mRNA expression was determined as
0.00001 mg/ml (10 ng/ml) for NHBE cells. Pacurari et al. (2008) have reported that the effect of
SWCNTs was greater in normal human mesothelial cells than in malignant mesothelial cells,
concerning genes involved in molecular signaling. However, the downregulatory effect on the P450
isoforms specifically was comparable between NHBE and A549 cells, which justifies the use of A549
cells for investigation of the mechanism of SWCNT action.
We further analyzed the mechanism of CYP1A1 and CYP1B1 downregulation because these genes
were most affected by SWCNT exposure. Since AhR is reported to be involved in the constitutive
expression of CYP1A1 (Zhang and Walker, 2007), the effect of SWCNTs on expression of AhR
mRNA was investigated. However, the effect of SWCNTs on basal AhR expression was negligible in
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
DMD#43455
16
NHBE and A549 cells, indicating that the downregulatory effect of SWCNTs on CYP1A1 mRNA was
not due to the suppression of AhR expression.
TCDD is the most potent ligand of the AhR receptor, and in the present study it was used to
characterize the effect of SWCNTs on the TCDD-induced expression of CYP1A1 and CYP1B1 using
A549, HepG2, and MCF-7 cells. HepG2 and MCF-7 cells were studied because they have been
extensively used in studies of CYP1A1 and CYP1B1 induction, and have well-characterized AhR
pathways. As previously reported, the AhR-mediated induction of CYP1A1 and CYP1B1 was greater
in HepG2 and MCF-7 cells than in A549 cells (Iwanari et al., 2002). Addition of SWCNTs
downregulated the TCDD-induced CYP1A1 and CYP1B1 mRNA expression in all 3 carcinoma cell
lines. The combined enzymatic activity of CYP1A1 and CYP1B1 was also reduced by SWCNTs in
HepG2 and MCF-7 cells, as measured using P450-Glo analysis (Fig. 7). Since HepG2 cells do not
express CYP1B1 mRNA (Beedanagari et al., 2009), the observed enzymatic activity in HepG2 cells is
presumably due to CYP1A1. The effect of SWCNTs on CYP1A1 and CYP1B1 mRNA and enzymatic
activity was more potent in TCDD-induced cells, indicating that an AhR-modulated pathway is
involved in the effect of SWCNTs on these genes.
Resveratrol, a phenolic phytoalexin, downregulates both constitutive and PAH-induced CYP1A1
expression, and thus has a chemopreventive effect by inhibiting procarcinogen activation (Mollerup et
al., 2001). Resveratrol has been reported to mediate this effect by preventing binding of activated
nuclear AhR to the xenobiotic responsive element of CYP1A1 (Beedanagari et al., 2009). Using ChIP
assays, SWCNTs repressed AhR binding to the CYP1A1 enhancer region in HepG2 cells, and to both
CYP1A1 and CYP1B1 enhancer regions in MCF-7 cells as in the case with resveratrol (Fig. 8). These
results indicate that inhibition of binding of activated AhR to the enhancer regions of these genes is at
least one of the mechanisms in downregulation of CYP1A1 and CYP1B1 mRNA and enzymatic
activity. It is notable that SWCNTs were not detected in the nucleus of NHBE cells (Fig. 1),
suggesting they were unlikely to directly compete with AhR binding to DNA.
A significant inverse relationship has been reported between the expression levels of miR-27b and
CYP1B1 protein (Tsuchiya et al., 2006), prompting us to investigate the effect of SWCNTs on this
microRNA. However, miR-27b expression was not changed by exposure to SWCNTs, indicating that
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
DMD#43455
17
the observed downregulation of CYP1B1 activity was not due to post-transcriptional regulation by
miR-27b (Fig. 9).
The phase II enzymes GSTA4 and GSTM3 were significantly upregulated in donor 1 NHBE cells
but not in NHBE cells derived from donor 2. The induction of phase II enzymes results in the
detoxification of carcinogens, leading to the protective effect of chemopreventive agents (Guidice and
Montella, 2006). Given the different effects of SWCNTs on phase II enzyme induction in our 2 NHBE
cell populations, it may be useful to investigate this further in cells derived from a larger group of
donors.
In conclusion, we clarified that exposure of primary cultured NHBE and A549 cells to SWCNTs
dysregulated some important drug-metabolizing enzymes expressed in human respiratory organs.
Exposure of SWCNTs downregulated the mRNA expression and enzymatic activity of CYP1A1 and
CYP1B1 in HepG2 and MCF-7 cells, as a consequence of preventing the binding of activated AhR to
the enhancer region of these genes. Downregulation of CYP1A1 and CYP1B1 genes by SWCNTs
may affect the defense mechanisms by reducing procarcinogen bio-activation in the human lung, and
additionally may alter the metabolism of drugs delivered to the respiratory organ. The present study
has provided some basic information on the effect of SWCNTs on drug-metabolizing enzymes in
respiratory organs. Clearly, the results support examination of the effects of SWCNTs on
drug-metabolizing enzymes at the target organ before their clinical application as drug carriers.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
DMD#43455
18
Authorship contributions
Participation in research design: Hitoshi, Katoh, and Nadai
Conducted experiments: Hitoshi and Katoh
Contributed new reagents or analytic tools: Suzuki and Ando
Performed data analysis: Hitoshi and Katoh
Wrote or contributed to the writing of the manuscript: Hitoshi, Katoh, and Nadai
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
DMD#43455
19
References
Alazzam A, Mfoumou E, Stiharu I, Kassab A, Darnel A, Yasmeen A, Sivakumar N, Bhat R, and Al
Moustafa AE (2010) Identification of deregulated genes by single wall carbon-nanotubes in human
normal bronchial epithelial cells. Nanomedicine 6:563-569.
Ando Y, Zhao X, Hirahara K, Suenaga K, Bandow S and Iijima S (2000) Mass production of
single-wall carbon nanotubes by the arc plasma jet method. Chem Phys Lett 323:580-585.
Beedanagari SR, Bebenek I, Bui P, and Hankinson O (2009) Resveratrol inhibits dioxin-induced
expression of human CYP1A1 and CYP1B1 by inhibiting recruitment of the aryl hydrocarbon
receptor complex and RNA polymerase II to the regulatory regions of the corresponding genes.
Toxicol Sci 110:61-67.
Bhirde AA, Patel S, Sousa AA, Patel V, Molinolo AA, Ji Y, Leapman RD, Gutkind JS, and Rusling JF
(2010) Distribution and clearance of PEG-single-walled carbon nanotube cancer drug delivery
vehicles in mice. Nanomedicine (Lond) 5:1535-1546.
Chen D, Reierstad S, Lu M, Lin Z, Ishikawa H, and Bulun SE (2009) Regulation of breast
cancer-associated aromatase promoters. Cancer Lett 273:15-27.
Cheng YW, Chen CY, Lin P, Huang KH, Lin TS, Wu MH, and Lee H (2000) DNA adduct level in
lung tissue may act as a risk biomarker of lung cancer. Eur J Cancer 36:1381-1388.
Cui D, Tian F, Ozkan CS, Wang M, and Gao H (2005) Effect of single wall carbon nanotubes on
human HEK293 cells. Toxicol Lett 155:73-85.
Davoren M, Herzog E, Casey A, Cottineau B, Chambers G, Byrne HJ, and Lyng FM (2007) In vitro
toxicity evaluation of single walled carbon nanotubes on human A549 lung cells. Toxicol In Vitro
21:438-448.
Giudice A and Montella M (2006) Activation of the Nrf2-ARE signaling pathway: a promising
strategy in cancer prevention. Bioassays 28:169-181.
Hitoshi K, Katoh M, Suzuki T, Ando Y, and Nadai M (2011) Differential Effects of Single-Walled
Carbon Nanotubes on Cell Viability of Human Lung and Pharynx Carcinoma Cell Lines. J Toxicol
Sci 36:379-387.
Hukkanen J, Pelkonen O, Hakkola J, and Raunio H (2002) Expression and regulation of
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
DMD#43455
20
xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. Crit Rev Toxicol
32:391-411.
Iijima S (1991) Helical microtubules of grafitic carbon. Nature 354:56-58.
Ikuta T, Ohba M, Zouboulis CC, Fujii-Kuriyama Y, and Kawajiri K (2010) B lymphocyte-induced
maturation protein 1 is a novel target gene of aryl hydrocarbon receptor. J Dermatol Sci 58:211-216.
Inoue Y, Miki C, Watanabe H, Hiro J, Toiyama Y, Ojima E, Yanagi H, and Kusunoki M (2006)
Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in a colon cancer cell line. J
Gastroenterol 41:1149-1157.
Iwanari M, Nakajima M, Kizu R, Hayakawa K, and Yokoi T (2002) Induction of CYP1A1, CYP1A2,
and CYP1B1 mRNAs by nitropolycyclic aromatic hydrocarbons in various human tissue-derived
cells: chemical-, cytochrome P450 isoform-, and cell-specific differences. Arch Toxicol 76:287-298.
Kasai T, Shozu M, Murakami K, Segawa T, Shinohara K, Nomura K, and Inoue M (2004) Increased
expression of type I 17beta-hydroxysteroid dehydrogenase enhances in situ production of estradiol
in uterine leiomyoma. J Clin Endocrinol Metab 89:5661-5668.
Klumpp C, Kostarelos K, Prato M, and Bianco A (2006) Functionalized carbon nanotubes as
emerging nanovectors for the delivery of therapeutics. Biochim Biophys Acta 1758:404-412.
Leclerc J, Tournel G, Courcot-Ngoubo Ngangue E, Pottier N, Lafitte JJ, Jaillard S, Mensier E,
Lhermitte M, Broly F, and Lo-Guidice JM (2010) Profiling gene expression of whole cytochrome
P450 superfamily in human bronchial and peripheral lung tissues: Differential expression in
non-small cell lung cancers. Biochimie 92:292-306.
Li LA (2007) Polychlorinated biphenyl exposure and CYP19 gene regulation in testicular and
adrenocortical cell lines. Toxicol In Vitro 21:1087-1094.
Li Z, Srivastava S, Yang X, Mittal S, Norton P, Resau J, Haab B, and Chan C (2007) A hierarchical
approach employing metabolic and gene expression profiles to identify the pathways that confer
cytotoxicity in HepG2 cells. BMC Syst Biol 1:21.
Liu J, Liu J, Chu L, Wang Y, Duan Y, Feng L, Yang C, Wang L, and Kong D (2011) Novel
peptide-dendrimer conjugates as drug carriers for targeting nonsmall cell lung cancer. Int J
Nanomedicine 6:59-69.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
DMD#43455
21
Liu Z, Sun X, Nakayama-Ratchford N, and Dai H (2007) Supramolecular chemistry on water-soluble
carbon nanotubes for drug loading and delivery. ACS Nano 1:50-56.
Lowe CR (2000) Nanobiotechnology: the fabrication and applications of chemical and biological
nanostructures. Curr Opin Struct Biol 10:428-434.
Matthews J, Wihlén B, Thomsen J, and Gustafsson JA (2005) Aryl hydrocarbon receptor-mediated
transcription: ligand-dependent recruitment of estrogen receptor alpha to 2,3,7,8-
tetrachlorodibenzo- p-dioxin-responsive promoters. Mol Cell Biol 25:5317-5328.
Mollerup S, Ovrebø S, and Haugen A (2001) Lung carcinogenesis: resveratrol modulates the
expression of genes involved in the metabolism of PAH in human bronchial epithelial cells. Int J
Cancer 92:18-25.
Okino ST, Pookot D, Li LC, Zhao H, Urakami S, Shiina H, Igawa M, and Dahiya R (2006) Epigenetic
inactivation of the dioxin-responsive cytochrome P4501A1 gene in human prostate cancer. Cancer
Res 66:7420-7428.
Pacurari M, Yin XJ, Zhao J, Ding M, Leonard SS, Schwegler–Berry D, Ducatman BS, Sbarra D,
Hoover MD, Castranova V, and Vallyathan V (2008) Raw single-wall carbon nanotubes induce
oxidative stress and activate MAPKs, AP-1, NF-kappaB, and Akt in normal and malignant human
mesothelial cells. Environ Health Perspect 116:1211-1217.
Pal L, Niklaus AL, Kim M, Pollack S, and Santoro N (2008) Heterogeneity in endometrial expression
of aromatase in polyp-bearing uteri. Hum Reprod 23:80-84.
Porter AE, Gass M, Muller K, Skepper JN, Midgley PA, and Welland M (2007) Direct imaging of
single-walled carbon nanotubes in cells. Nat Nanotechnol 2:713-717.
Saarikoski ST, Rivera SP, Hankinson O, and Husgafvel-Pursiainen K (2005) CYP2S1: a short review.
Toxicol Appl Pharmacol 207:62-69.
Sarkar S, Sharma C, Yog R, Periakaruppan A, Jejelowo O, Thomas R, Barrera EV, Rice-Ficht AC,
Wilson BL, and Ramesh GT (2007) Analysis of stress responsive genes induced by single-walled
carbon nanotubes in BJ Foreskin cells. J Nanosci Nanotechnol 7:584-592.
Shimada T, Hayes CL, Yamazaki H, Amin S, Hecht SS, Guengerich FP, and Sutter TR (1996)
Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
DMD#43455
22
56:2979-2984.
Schmidt AJ, Hemmeter UM, Krieg JC, Vedder H, and Heiser P (2009) Impact of haloperidol and
quetiapine on the expression of genes encoding antioxidant enzymes in human neuroblastoma
SH-SY5Y cells. J Psychiatr Res 43:818-823.
Thum T, Erpenbeck VJ, Moeller J, Hohlfeld JM, Krug N, and Borlak J (2006) Expression of
xenobiotic metabolizing enzymes in different lung compartments of smokers and nonsmokers.
Environ Health Perspect 114:1655-1661.
Tsuchiya Y, Nakajima M, Kyo S, Kanaya T, Inoue M, and Yokoi T (2004) Human CYP1B1 is
regulated by estradiol via estrogen receptor. Cancer Res 64:3119-3125.
Tsuchiya Y, Nakajima M, Takagi S, Taniya T, and Yokoi T (2006) MicroRNA regulates the expression
of human cytochrome P450 1B1. Cancer Res 66:9090-9098.
Wilkening S, Stahl F, and Bader A (2003) Comparison of primary human hepatocytes and hepatoma
cell line Hepg2 with regard to their biotransformation properties. Drug Metab Dispos 31:1035-1042.
Xu C, Li CY, and Kong AN (2005) Induction of phase I, II and III drug metabolism/transport by
xenobiotics. Arch Pharm Res 28:249-268.
Zhang N and Walker MK (2007) Crosstalk between the aryl hydrocarbon receptor and hypoxia on the
constitutive expression of cytochrome P4501A1 mRNA. Cardiovasc Toxicol 7:282-290.
Zieker D, Fehrenbach E, Dietzsch J, Fliegner J, Waidmann M, Nieselt K, Gebicke-Haerter P, Spanagel
R, Simon P, Niess AM, and Northoff H (2005) cDNA microarray analysis reveals novel candidate
genes expressed in human peripheral blood following exhaustive exercise. Physiol Genomics
23:287-294.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
DMD#43455
23
Footnotes
This work was supported by the Grant-in-Aid for Young Scientists (B)[Grant 21790167] and the
Grant-in-Aid for Scientific Research (C) [Grant 21590183] from Japan Society for the Promotion of
Science.
Reprint request to Miki Katoh, Ph. D., Pharmaceutics, Faculty of Pharmacy, Meijo University; 150
Yagotoyama, Tenpaku-ku, Nagoya 468–8503, Japan. E-mail: [email protected]
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
DMD#43455
24
Figure legends
Fig. 1. TEM micrograph of NHBE cells after exposure to 0.1 mg/ml SWCNTs for 24 h. (A)
untreated, (B) SWCNT exposed cells. Representative pinocytotic vesicles are indicated by the circle.
Fig. 2. PCR array analysis of 84 drug-metabolizing enzymes after 24-h exposure of NHBE cells to
SWCNTs. Closed circles represent genes that were upregulated (●) or downregulated (●) by more
than 2-fold compared to untreated control cells.
Fig. 3. Real-time PCR analysis of drug-metabolizing enzymes in NHBE (donor 1) (A), NHBE
(donor 2) (B), and A549 cells (C). The open and filled columns represent untreated control and
SWCNT exposure, respectively. Each column represents mean ± S.D. (n = 3). * p < 0.05 compared to
untreated control cells.
Fig. 4. Dose-responsive effects of SWCNTs on CYP1A1 and CYP1B1 mRNA expression in NHBE
and A549 cells. Expression levels of CYP1A1 (closed symbols) and CYP1B1 (open symbols) are
represented by squares (NHBE cells) and circles (A549 cells), respectively. *, p < 0.05 compared to
untreated control.
Fig. 5. Basal CYP1A1, CYP1B1, and AhR mRNA expression in A549 (A), HepG2 (B), and MCF-7
(C) cells after exposure to SWCNTs for 24 h. Each column represents mean ± S.D. (n = 3). *, p < 0.05
compared to untreated control.
Fig. 6. TCDD-induced CYP1A1 and CYP1B1 mRNA expression in A549 (A), HepG2 (B), and
MCF-7 (C) cells after exposure to SWCNTs for 24 h. Cells were exposed to 10 nM TCDD for
induction of CYP1A1 and CYP1B1. Each column represents mean ± S.D. (n = 3). *, p < 0.05
compared to TCDD-induced cells.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
DMD#43455
25
Fig. 7. CYP1A1 and CYP1B1 enzymatic activity in TCDD-induced HepG2 (A) and MCF-7 (B)
cells after exposure to SWCNTs for 24 h. Cells were exposed to 10 nM TCDD for induction of
CYP1A1 and CYP1B1. Each column represents mean ± S.D. (n = 3). *, p < 0.05 compared to
TCDD-induced cells.
Fig. 8. Effect of SWCNTs on TCDD-induced recruitment of AhR to the enhancer region of
CYP1A1 in HepG2 cells (A) or to the enhancer regions of CYP1A1 and CYP1B1 in MCF-7 cells (B).
Cells were exposed to 10 nM TCDD for induction of CYP1A1 and CYP1B1. The results were
expressed relative to those of the total input controls. Each column represents mean ± S.D. (n = 3). *,
p < 0.05 compared to TCDD-induced cells.
Fig. 9. MiR-27b expression in TCDD-induced MCF-7 cells after exposure to SWCNTs for 24 h.
Cells were exposed to 10 nM TCDD for induction of CYP1B1. Each column represents mean ± S.D.
(n = 3).
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
DMD#43455
26
TABLE 1 Physicochemical properties of SWCNTs used in the present study.
Diametera Lengthb SWCNT purityb Metal catalyst residuec (nm) (µm) (%) (atom %)
SO-SWCNT 1.36–1.42 1–5 >90 Nickel: 0.56 ± 0.09 Yttrium: 0.16 ± 0.05 a Range (n = 5). b Referential value provided from the manufacturer. c Mean ± SD (n = 10).
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
DMD#43455
27
TABLE 2
Sequences of primers and PCR conditions used in the present study
Gene Primer sequence Annealing temp. (°C)
Annealing time (sec)
Amplicon size (bp)
References
AhR Sense Antisense
5'-ATA CTG AAG CAG AGC TGT GC-3' 5'-AAA GCA GGC GTG CAT TAG AC -3'
60 60 183 Ikuta et al. (2010)
ALDH1A1 Sense Antisense
5'-AGC CTT CAC AGG ATC AAC AGA-3' 5'-GTC GGC ATC AGC TAA CAC AA-3'
60 60 124 Li et al. (2007)
CES2 Sense Antisense
5'-AGT GGT GTG AGG GAT GGA AC-3' 5'-TGG CTA AGA AAC TCT GAC TCC A-3'
60 60 80 Inoue et al. (2006)
CYP1A1 Sense Antisense
5'-TTC GTC CCC TTC ACC ATC-3' 5'-CTG AAT TCC ACC CGT TGC-3'
60 90 302 Wilkening et al. (2003)
CYP1B1 Sense Antisense
5'-GAG AAC GTA CCG GCC ACT ATC-3' 5'-CGG GTT AGG CCA CTT CAG T-3'
60 60 357
CYP2S1 Sense Antisense
5'-ACC CCA ACA TCT TCA AGC AC-3' 5'-TTC ATC TGG TCT GCG TGG T-3'
62 60 312 Thum et al. (2006)
CYP19A1 Sense Antisense
5'-AGG AGG TGA CCA ATG AAT CG-3' 5'-CAC GAT AGC ACT TTC GTC CA-3'
62 60 116 Pal et al. (2008)
GSR Sense Antisense
5'-CAG TGG GAC TCA CGG AAG AT-3' 5'-TTC ACT GCA ACA GCA AAA CC-3'
60 60 219 Schmidt et al. (2009)
GSTA4 Sense Antisense
5'-CCG GAT GGA GTC CGT GAG-3' 5'-CTT CGG GTC TGT ACC AAC TT-3'
60 60 168
GSTM3 Sense Antisense
5'-CCT GGA TGG GAA GAA CAA GA-3' 5'-TTG TGT GCG GAA ATC CAT TA-3'
60 60 142 Zieker et al. (2005)
HSD17B3 Sense Antisense
5'-ACC TTC TCC CAA GCC ATT TC-3' 5'-AAC GCC TTG GAA GCT GAG TA-3'
62 60 202 Kasai et al. (2004)
GAPDH Sense Antisense
5'-CCA GGG CTG CTT TTA ACT C-3' 5'-GCT CCC CCC TGC AAA TGA-3'
60 60 289 Tsuchiya et al. (2004)
This article has not been copyedited and form
atted. The final version m
ay differ from this version.
DM
D Fast Forw
ard. Published on Decem
ber 20, 2011 as DO
I: 10.1124/dmd.111.043455
at ASPET Journals on July 12, 2020 dmd.aspetjournals.org Downloaded from
DMD#43455
28
TABLE 3
Changes in the expression of drug-metabolizing enzymes in NHBE cells by PCR array
Gene Fold change Up-regulated ALDH1A1 2.99 GSTA4 2.12 HSD17B3 2.05 Alcohol dehydrogenase 1C (class I), gamma polypeptide 2.01 Down-regulated CYP1A1 0.002 Alcohol dehydrogenase 4 (class II), pi polypeptide 0.11 Amiloride binding protein 1 (amine oxidase (copper-containing)) 0.16 CYP19A1 0.21 Glucokinase (hexokinase 4) regulator 0.27 Pyruvate kinase, liver and RBC 0.31 GSR 0.32 CYP11B2 0.33 GSTM3 0.35 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 0.43 CES2 0.44 Metallothionein 3 0.46 Hexokinase 2 0.47 Hydroxysteroid (17-beta) dehydrogenase 2 0.48 5,10-methylenetetrahydrofolate reductase (NADPH) 0.49
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on December 20, 2011 as DOI: 10.1124/dmd.111.043455
at ASPE
T Journals on July 12, 2020
dmd.aspetjournals.org
Dow
nloaded from